CVS Health Corporation (NYSE:CVS) saw its stock hit a 52-week high after launching a pharmacy-focused Houston store with pet prescriptions, reporting solid fiscal Q2 results (~$100.7B revenue, $1.84 EPS) and a $10M affordable-housing investment, while UBS raised its price target to $122.
Previous Week Recap
- CVS Launches Pharmacy Store In Houston: CVS launched a pharmacy-focused store in Houston, added pet prescriptions, prepared fiscal Q2 results (revenue ~$100.7B, EPS $1.84) and hit a 52-week high, stock up ~2%.
- UBS Raises CVS Target To 122: UBS reiterated a Buy rating on CVS Health Corporation (CVS) and raised its price target to $122.00 per share from $115.00, updating its valuation and recommendation for the stock.
- CVS Funds 80 Affordable Housing Units: CVS Health (CVS) invested $10M to fund 80 affordable housing units in Worcester, MA, targeting adults 55+ with five units set aside for Massachusetts Department of Mental Health-connected households.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.